長崎大学大学院医歯薬学総合研究科医療科学専攻 腫瘍医学分野

ENGLISH
HOME＞業績

業　績

論文発表

  1. S Okada,D Muraoka,K Yasui,I Tawara,A Kawamura,S Okamoto,J Mineno,N Seo,H Shiku,S Eguchi,H Ikeda.
    T cell receptor gene-modified allogeneic T cells with siRNA for endogenous T cell receptor induce efficient tumor regression without graft-versus-host disease.
    Cancer Science.2023 Nov;114(11):4172-4183. doi: 10.1111/cas.15954. Epub 2023 Sep 7.

  2. S Okumura, M Ishihara, N Kiyota, K Yakushijin, K Takada, S Kobayashi, H Ikeda, M Endo, K Kato, S Kitano, A Matsumine, Y Nagata, S Kageyama, T Shiraishi, T Yamada, K Horibe, K Takesako, H Miwa, T Watanabe, Y Miyahara, H Shiku.
    Chimeric antigen receptor T-cell therapy targeting a MAGE A4 peptide and HLA-A*02:01 complex for unresectable advanced or recurrent solid cancer: protocol for a multi-institutional phase 1 clinical trial.
    BMJ Open.2022 Nov;114(11):4172-4183. doi: 10.1111/cas.15954. Epub 2023 Sep 7.

  3. M Ishihara, S Kitano, S Kageyama, Y Miyahara, N Yamamoto, H Kato, H Mishima, H Hattori, T Funakoshi, T Kojima, T Sasada, E Sato, S Okamoto, D Tomura, I Nukaya, H Chono, J Mineno, Muhammad Faris Kairi, Phuong Diem Hoang Nguyen, Yannick Simoni, Alessandra Nardin, Evan Newell, Michael Fehlings, H Ikeda, T Watanabe, H Shiku.
    NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome.
    Journal for immunotherapy of cancer.2022 Jun;10(6):e003811. doi: 10.1136/jitc-2021-003811.

  4. Nagata Y, Kageyama S, Ishikawa T, Kokura S, Okayama T, Abe T, Murakami M, Otsuka K, Ariyoshi T, Kojima T, Taniguchi K, Kobayashi S, Shimada H, Yajima S, Suzuki T, Hirano S, Tsuchikawa T, Shichinohe T, Ueda S, Kanetaka K, Yoneda A, Wada H, Doki Y, Yamaue H, Katsuda M, Ohi M, Yasuda H, Kondo K, Kataoka M, Kodera Y, Koike M, Shiraishi T, Miyahara Y, Goshima N, Fukuda E, Yamaguch K, Sato E, Ikeda H, Yamada T, Osako M, Hirai K, Miyamoto H, Watanabe T, Shiku H.
    Prognostic significance of NY-ESO-1 antigen and PIGR expression in esophageal tumors of CHP-NY-ESO-1–vaccinated patients as adjuvant therapy.
    Cancer Immunology, Immunotherapy.2022 Apr 16. doi: 10.1007/s00262-022-03194-5.

  5. Yosuke Dotsu,Daisuk Muraoka,Naohisa Ogo,Yudai Sonoda,Kiyoshi Yasui,Hiroyuki Yamaguchi,Hideo Yagita,Hiroshi Mukae,Akira Asai, Hiroaki Ikeda.
    Chemical augmentation of mitochondrial electron transport chains tunes T cell activation threshold in tumors.
    Journal for immunotherapy of cancer. 2022 Feb ;10(2):e003958. doi: 10.1136/jitc-2021-003958.

  6. Yosuke Dotsu,Hiroyuki Yamaguchi, Minoru Fukuda, Takayuki Suyama, Noritaka Honda, Yasuhiro Umeyama, Hirokazu Taniguchi, Hiroshi Gyotoku, Shinnosuke Takemoto, Ryuta Tagawa, Ryosuke Ogata, Hiromi Tomono, Midori Shimada, Hiroaki Senju, Katsumi Nakatomi, Seiji Nagashima, Hiroshi Soda , Hiroaki Ikeda, Kazuto Ashizawa, Hiroshi Mukae.
    Real-world Incidence of Febrile Neutropenia among Patients treated with Single-agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-stimulating Factor.
    Journal of Clinical Medicine. 2021 Sep 17;10(18):4221. doi: 10.3390/jcm10184221.

  7. Yosuke Dotsu, Minoru Fukuda, Noritaka Honda, Hiroshi Gyotoku, Yoshihisa Kohno, Takayuki Suyama, Yasuhiro Umeyama, Hirokazu Taniguchi, Shinnosuke Takemoto, Hiroyuki Yamaguchi, Taiga Miyazaki, Noriho Sakamoto, Yasushi Obase, Hiroaki Ikeda, Kazuto Ashizawa, Hiroshi Mukae.
    Dabrafenib and trametinib therapy for an elderly patient with non-small cell lung cancer harboring the BRAF V600E mutation.
    Thoracic Cancer. 2020, 12(2):272-276. doi: 10.1111/1759-7714.13756.

  8. DaisukeMuraoka,Deng Situo, Shin-ichi Sawada, Kazunari Akiyoshi, NaozumiHarada, HiroakiIkeda.
    Identification of a dominant CD8+ CTL epitope in the SARS-associated coronavirus 2 spike protein.
    Vaccine.2020 Nov 17;38(49): 7697-7701 . doi: 10.1016/j.vaccine.2020.10.039.

  9. Mikiya Ishihara, Shinichi Kageyama, Yoshihiro Miyahara, Takeshi Ishikawa, Shugo Ueda, Norihito Soga, Hiroaki Naota, Katsumi Mukai, Naozumi Harada, HiroakiIkeda、Hiroshi Shiku.
    MAGE-A4, NY-ESO-1 and SAGE mRNA expression rates and co-expression relationships in solid tumours.
    BMC Cancer.2020, 20:607. doi:10.1186/s12885-020-07098-4.

  10. Naoko Imai, Isao Tawara, Makiko Yamane, Daisuke Muraoka, Hiroshi Shiku, HiroakiIkeda.
    CD4+ T cells support polyfunctionality of cytotoxic CD8+ T cells with memory potential in immunological control of tumor.
    Cancer Sci.2020, 111:1958-1968. doi: 10.1111/cas.14420.

  11. Ishihara M, Tono Y, Miyahara Y, Muraoka D, Harada N, Kageyama S, Sasaki T, Hori Y, Soga N, Uchida K, Shiraishi T, Sato E, Kanda H, Mizuno T, Webster GA, Ikeda H, Katayama N, Sugimura Y, Shiku H.
    First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors..
    Cancer Immunol Immunother. 2020 Apr ;69(4):663-675. doi: 10.1007/s00262-020-02483-1.

  12. Kakimoto T, Matsumine A, Kageyama S, Asanuma K, Matsubara T, Nakamura T, Iino T, Ikeda H, Shiku H, Sudo A.
    Immunohistochemical expression and clinicopathological assessment of the cancer testis antigens NY-ESO-1 and MAGE-A4 in high-grade soft-tissue sarcoma.
    Oncol Lett.2019 Apr;17(4):3937-3943. doi:10.3892/ol.2019.10044.

  13. Muraoka D,Seo N, Hayashi T, Tahara Y, Fujii K, Tawara I, Miyahara Y, Okamori K, Yagita H, Imoto S, Yamaguchi R, Komura M, Miyano S, Goto M, Sawada SI, Asai A, Ikeda H, Akiyoshi K, Harada N, Shiku H.
    Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance.
    J Clin Invest.2019 Jan 10. pii: 97642. doi: 10.1172/JCI97642.

  14. Ueda S, Miyahara Y, Nagata Y, Sato E, Shiraishi T, Harada N, Ikeda H, Shiku H, Kageyama S.
    NY-ESO-1 antigen expression and immune response are associated with poor prognosis in MAGE-A4-vaccinated patients with esophageal or head/neck squamous cell carcinoma.
    Oncotarget.2018 Nov 13;9(89):35997-36011. doi: 10.18632/oncotarget.26323.

  15. Akahori Y, Wang L, Yoneyama M, Seo N, Okumura S, Miyahara Y, Amaishi Y, Okamoto S, Mineno J, Ikeda H, Maki T, Fujiwara H, Akatsuka Y, Kato T, Shiku H.
    Antitumor activity of CAR-T cells targeting the intracellular oncoprotein WT1 can be enhanced by vaccination.
    Blood.2018 Sep 13;132(11):1134-1145. doi:10.1182/blood-2017-08-802926.

  16. Fujiwara-Kuroda A, Kato T, Abiko T, Tsuchikawa T, Kyogoku N, Ichinokawa M, Tanaka K, Noji T, Hida Y, Kaga K, Matsui Y, Ikeda H, Kageyama S, Shiku H, Hirano S.
    Prognostic value of MAGEA4 in primary lung cancer depends on subcellular localization and p53 status.
    Int J Oncol.2018 Aug ;53(2):713-724. doi:10.3892/ijo.2018.4425.

  17. Yasui K, Izumida M, Nakagawa T, Kubo Y, Hayashi H, Ito T, Ikeda H, Matsuyama T.
    MicroRNA-3662 expression correlates with antiviral drug resistance in adult T-cellleukemia/lymphoma cells.
    Biochem Biophys Res Commun.2018 Jul 2;501(4):833-837. doi: 10.1016/j.bbrc.2018.04.159.

  18. Tono Y, Ishihara M, Miyahara Y, Tamaru S, Oda H, Yamashita Y, Tawara I, Ikeda H, Shiku H, Mizuno T, Katayama N.
    Pertuzumab, trastuzumab and eribulin mesylate therapy for previously treated advanced HER2-positive breast cancer: a feasibility study with analysis of biomarkers.
    Oncotarget.2018 Feb 16;9(19):14909-14921. doi: 10.18632/oncotarget.24504.

  19. Wada M, Tsuchikawa T, Kyogoku N, Abiko T, Miyauchi K, Takeuchi S, Kuwatani T, Shichinohe T, Miyahara Y, Kageyama S, Ikeda H, Shiku H, Hirano S.
    Clinical implications of CD4+CD25+Foxp3+ regulatory T cell frequencies after CHP-MAGE-A4 cancer vaccination.
    Anticancer Res.2018 Mar;38(3):1435-1444 doi: 10.21873/anticanres.12368.

  20. Abiko T, Tsuchikawa T, Miyauchi K, Wada M, Kyogoku N, Shichinohe T, Miyahara Y, Kageyama S, Ikeda H, Shiku H, Hirano S.
    Serum immunoglobulin E response as a marker for unfavorable prognosis following cholesteryl pullulan-MAGE A4 vaccination.
    Oncol Lett.2018 Mar;15(3):3703-3711. doi: 10.3892/ol.2018.7767.

  21. Seo N, Shirakura Y, Tahara Y, Momose F, Harada N, Ikeda H, Akiyoshi K, Shiku H.
    Activated CD8+ T cell extracellular vesicles prevent tumour progression by targeting of lesional mesenchymal cells.
    Nat Commun.2018 Jan 30;9(1):435. doi: 10.1038/s41467-018-02865-1.

  22. Tawara I, Kageyama S, Miyahara Y, Fujiwara H, Nishida T, Akatsuka Y, Ikeda H, Tanimoto K, Terakura S, Murata M, Inaguma Y, Masuya M, Inoue N, Kidokoro T, Okamoto S, Tomura D, Chono H, Nukaya I, Mineno J, Naoe T, Emi N, Yasukawa M, Katayama N, Shiku H.
    Safety and persistence of WT1-specific T-cell receptor gene−transduced lymphocytes in patients with AML and MDS.
    Blood.2017 Nov 2;130(18):1985-1994. doi: 10.1182/blood-2017-06-791202.

  23. Takeda K, Nakayama M, Hayakawa Y, Kojima Y, Ikeda H, Imai N, Ogasawara K, Okumura K, Thomas DM, Smyth MJ.
    IFN-g is required for cytotoxic T cell-dependent cancer genome immunoediting.
    Nat commun.2017 Feb 24;8:14607. doi: 10.1038/ncomms14607.

  24. Maki T, Ikeda H, Kuroda A, Kyogoku N, Yamamura Y, Tabata Y, Abiko T, Tsuchikawa T, Hida Y, Shichinohe T, Tanaka E, Kaga K, Hatanaka K, Matsuno Y, Imai N, Hirano S.
    Differential detection of cytoplasmic Wilms tumor 1 expression by immunohistochemistry, Western blotting, and mRNA quantification.
    Int J Oncol.2017 Jan;50(1):129-140. doi: 10.3892/ijo.2016.3786.

  25. Kyogoku N, Ikeda H, Tsuchikawa T, Abiko T, Fujiwara A, Maki T, Yamamura Y, Ichinokawa M, Tanaka K, Imai N, Miyahara Y, Kageyama S, Shiku H, Hirano S.
    Time-dependent transition of the immunoglobulin G subclass and immunoglobulin E response in cancer patients vaccinated with cholesteryl pullulan-melanoma antigen gene-A4 nanogel.
    Oncol Lett.2016 Dec;12(6):4493-4504. doi: 10.3892/ol.2016.5253.

  26. Ikeda H.
    T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells.
    Int Immunol. 2016 May;8(5):527-40. doi: 10.1093/intimm/dxw022.

  27. Miyauchi K, Tsuchikawa T, Wada M, Abiko T, Kyogoku N, Shichinohe T, Miyahara Y, Kageyama S, Ikeda H, Shiku H, Hirano S.
    Clinical relevance of antigen spreading pattern induced by CHP-MAGE-A4 cancer vaccination.
    Immunotherapy. 2016 May;8(5):527-40. doi: 10.2217/imt-2016-0007.

  28. Arato T, Daimon T, Heike Y, Ishii K, Itho K, Kageyama S, Kawakami Y, Nakayama E, Ozawa K, Sato N, Shiku H, Takeuchi M, Tani K, Tamada K, Ueda R, Yamaguchi Y, Yamanaka T, Yamaue H, Yasukawa M, Iguchi T, Kitano S, Miyahara Y, Nagata Y, Noguchi M, Terashima T, Asano T, Asonuma M, Ikeda H, Kakimi K, Takesako K, Tanaka M, Amakasu K, Yamada A, Harada N, Aoshi T, Kuroda E, Kobiyama K, Muraoka D, Yamazaki N, Kuchiba A, Tanaka S, Michimae H, Yamada T, Hanada K, Okada H, Takebe N, Hirano N, Okumura S, Sato D, Shibatsuji M, Yamaguchi T.
    2015 Guidance on cancer immunotherapy development in early‐phase clinical studies.
    Cancer Sci.2015 Dec;106(12):1761-71. doi: 10.1111/cas.12819.

  29. Ikeda H, Shiku H.
    Adoptive immunotherapy of cancer utilizing genetically engineered lymphocytes.
    Cancer Immunol Immunother.2015 Jul;64(7):903-9. doi: 10.1007/s00262-015-1718-0.

  30. Kageyama S, Ikeda H, Miyahara Y, Imai N, Ishihara M, Saito K, Sugino S, Ueda S, Ishikawa T, Kokura S, Naota H, Ohishi K, Shiraishi T, Inoue N, Tanabe M, Kidokoro T, Yoshioka H, Tomura D, Nukaya I, Mineno J, Takesako K, Katayama N, Shiku H.
    Adoptive transfer of MAGE-A4 T-cell receptor gene−transduced lymphocytes in patients with recurrent esophageal cancer.
    Clin Cancer Res.2015 May 15;21(10):2268-77. doi: 10.1158/1078-0432.CCR-14-1559.

  31. Ishihara M, Seo N, Mitsui J, Muraoka D, Tanaka M, Mineno J, Ikeda H, Shiku H.
    Systemic CD8+ T Cell-Mediated Tumoricidal Effects by Intratumoral Treatment of Oncolytic Herpes Simplex Virus with the Agonistic Monoclonal Antibody for Murine Glucocorticoid-Induced Tumor Necrosis Factor Receptor.
    PLoS One.2014 Aug 8;9(8):e104669. doi: 10.1371/journal.pone.0104669.

  32. O'Sullivan T, Saddawi-Konefka R, Gross E, Tran M, Mayfield SP, Ikeda H, Bui JD.
    Interleukin-17D mediates tumor rejection through recruitment of natural killer cells.
    Cell Rep. 2014 May 22;7(4):989-98. doi: 10.1016/j.celrep.2014.03.073.

  33. Hosoi H, Ikeda H, Imai N, Amaike C, Wang L, Orito Y, Yamane M, Ueno H, Ideno M, Nukaya I, Enoki T, Mineno J, Takesako K, Hirano S, Shiku H.
    Stimulation through very late antigen-4 and -5 improves the multifunctionality and memory formation of CD8+ T cells.
    Eur J Immunol.2014 Jun;44(6):1747-58. doi: 10.1002/eji.201343969.

  34. Asai H, Fujiwara H1, Kitazawa S, Kobayashi N, Ochi T, Miyazaki Y, Ochi F, Akatsuka Y, Okamoto S, Mineno J, Kuzushima K, Ikeda H, Shiku H, Yasukawa M.
    Adoptive transfer of genetically engineered WT1-specific T lymphocytes does not induce renal injury.
    J Hematol Oncol.2014 Jan 6;7:3. doi: 10.1186/1756-8722-7-3.

  35. Kageyama S, Wada H, Muro K, Niwa Y, Ueda S, Miyata H, Takiguchi S, Sugino SH, Miyahara Y, Ikeda H, Imai N, Sato E, Yamada T, Osako M, Ohnishi M, Harada N, Hishida T, Doki Y, Shiku H.
    Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients.
    J Transl. Med.2013 Oct 5;11:246. doi: 10.1186/1479-5876-11-246.

  36. Iwami K, Natsume A, Ohno M, Ikeda H, Mineno J, Nukaya I, Okamoto S, Fujiwara H, Yasukawa M, Shiku H, Wakabayashi T, Wakabayashi T.
    Adoptive transfer of genetically modified Wilms' tumor 1-specific T cells in a novel malignant skull base meningioma model.
    Neuro Oncol..2013 Jun;15(6):747-58. doi: 10.1093/neuonc/not007.

  37. Soga N, Hori Y, Yamakado K, Ikeda H, Imai N, Kageyama S, Nakase K, Yuta A, Hayashi N, Shiku H, Sugimura Y.
    Limited expression of cancer-testis antigen in renal cell carcinoma patients.
    Mol Clin Oncol.2013 Mar;1(2):326-330. doi: 10.3892/mco.2012.40.

  38. Okamoto S, Amaishi Y, Goto Y, Ikeda H, Fujiwara H, Kuzushima K, Yasukawa M, Shiku H, Mineno J.
    A promising vector for TCR gene therapy: Differential effect of siRNA, 2A peptide, and disulfide bond on the introduced TCR expression.
    Mol Ther Nucleic Acids.2012 Dec 18;1:e63. doi: 10.1038/mtna.2012.52.

  39. Shirakura Y, Mizuno Y, Wang L, Imai N, Amaike C, Sato E, Ito M, Nukaya I, Mineno J, Takesako K, Ikeda H, Shiku H.
    T-cell receptor gene therapy targeting melanoma-associated antigen-A4 inhibits human tumor growth in non-obese diabetic/SCID/γcnull mice.
    Cancer Sci.2012 Jan;103(1):17-25. doi: 10.1111/j.1349-7006.2011.02111.x.

  40. Ikeda H.
    Gene-modified lymphocytes: from caution to promise for effective cancer immunotherapy.
    Immunotherapy.2012 Mar;4(3):241-4. doi: 10.2217/imt.12.1.

  41. Noguchi T, Kato T, Wang L, Maeda Y, Ikeda H, Sato E, Knuth A, Gnjatic S, Ritter G, Sakaguchi S, Old LJ, Shiku H, Nishikawa H, Old LJ, Shiku H, Nishikawa H.
    Intracellular tumor-associated antigens represent effective targets for passive immunotherapy.
    Cancer Res.2012 Apr 1;72(7):1672-82. doi: 10.1158/0008-5472.CAN-11-3072.

  42. Iwamura K, Kato T, Miyahara Y, Naota H, Mineno J, Ikeda H, Shiku H.
    siRNA-mediated silencing of PD-1 ligands enhances tumor-specific human T cell effector functions.
    Gene Ther.2012 Oct;19(10):959-66. doi: 10.1038/gt.2011.185.

  43. Tsuchikawa T, Ikeda H, Cho Y, Miyamoto M, Shichinohe T, Hirano S, Kondo S.
    Association of CD8+ T cell infiltration in esophageal carcinomalesions with HLA class I antigen expression and survival.
    Clin Exp Immunol.2011 Apr;164(1):50-6. doi: 10.1111/j.1365-2249.2010.04311.x

  44. Ikeda H, Shiku H.
    Antigen-receptor gene-modified T cells for treatment of glioma.
    Adv Exp Med Biol.2012;746:202-15. doi: 10.1007/978-1-4614-3146-6_16.

  45. Ikeda H, Okamoto S, Mineno J, Imai N, Ito M, Yasukawa M, Takesako K, Shiku H.
    Adoptive immunotherapy for cancer with genetically engineered T cells.
    Rinsho Ketsueki.2010 Nov;51(11):1647-53.

  46. Ikeda H,Imai N, Shiku H.
    Cancer treatment with gene-modified T cells or DNA vaccine.
    Nihon Rinsho.2010 Aug;68 Suppl 8:634-40.

  47. Okamoto S, Mineno J, Ikeda H, Fujiwara H, Yasukawa M, Shiku H, Kato I.
    Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by silencing of endogenous TCR.
    Cancer Res.2009 Dec 1;69(23):9003-11. doi: 10.1158/0008-5472.CAN-09-1450.

  48. Aoki M, Ueda S, Nishikawa H, Kitano S, Hirayama M, Ikeda H, Toyoda H, Tanaka K, Kanai M, Takabayashi A, Imai H, Shiraishi T, Sato E, Wada H, Nakayama E, Takei Y, Katayama N, Shiku H, Kageyama S. Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER2 with OK-432.
    Vaccine.2009 Nov 16;27(49):6854-61. doi: 10.1016/j.vaccine.2009.09.018.

  49. Imai N, Ikeda H, Tawara I, Wang L, Wang L, Nishikawa H, Kato T, Shiku H.
    GITR stimulation enhances multifunctionality of adoptively transferred tumor antigen-specific CD8+ T cells with tumor regression.
    Cancer Sci.2009 Jul;100(7):1317-25. doi: 10.1111/j.1349-7006.2009.01179.x.

  50. Imai N, Ikeda H, Tawara I, Shiku H.
    Tumor progression inhibits the induction of multifunctionality in adoptively transferred tumor-specific CD8+ T cells.
    Eur J Immunol.2009 Jan;39(1):241-53. doi: 10.1002/eji.200838824.

政策提言

  1. ネオアンチゲン等の新たながん免疫療法の標的　池田裕明　厚生労働省医薬品等審査迅速化事業費補助金　革新的医薬品・医療機器・再生医療製品実用化促進事業　公開シンポジウム　がん免疫療法2017　−複合化と個別化の科学基盤とレギュレーション− 2017/2/20　東京.
  2. がん免疫療法開発のガイダンス2016〜がん免疫療法に用いる細胞製品の品質、非臨床試験 の考え方〜　池田裕明　厚生労働省医薬品等審査迅速化事業費補助金　革新的医薬品・医療機器・再生医療製品実用化促進事業　公開シンポジウム　がん免疫療法2017　−複合化と個別化の科学基盤とレギュレーション− 2017/2/20　東京.
  3. 荒戸照世、石井健、伊東恭吾、上田龍三、小澤敬也、河上裕、佐藤昇志、竹内正弘、谷憲三朗、玉田耕治、大門貴志、中山睿一、平家勇司、安川正貴、山上裕機、山口佳之、山中竹春、浅野武夫、阿曽沼元博、井口豊崇、垣見和宏、北野滋久、竹迫一任、田中雅教、寺島健志、永田康浩、野口正典、池田裕明、宮原慶裕、口羽文、竹内正弘、大門貴志、田中司朗、道前洋史、山田知美、山中竹春、甘粕晃平、山田亮、原田直純、青枝大貴、石井健、黒田悦史、小檜山康司、村岡大輔、山﨑直也、奥村悟司、太田百合絵、百瀬文康、影山愼一、珠玖洋　がん免疫療法開発のガイダンス2015　早期臨床試験の考え方　〜安全で効果的な開発を目指して〜　厚生労働省医薬品等審査迅速化事業費補助金　革新的医薬品・医療機器・再生医療製品実用化促進事業　研究報告書　2015年

メディアでの公表

  1. R4年4月12日富山新聞にて「免疫細胞検出に新技術」内容に対する、池田教授のコメントが掲載。
    ◆富山新聞記事
  2. R4年1月1日科学新聞にて「難治性固形がんに対する先端的CAR-T細胞療法に関する研究開発」として、長崎大学が代表で進める研究が掲載。
    ◆科学新聞記事
  3. H30年1月29日日本経済新聞朝刊にて「白血病、遺伝子治療安く」として長崎大学が代表で進める細胞療法の医師主導治験が掲載。
  4. H27年11月21日日経バイオテクにて「TCR療法とCARに熱視線　国内での実用化には課題も浮上」として長崎大学が進める細胞療法が掲載。
  5. H27年11月日経バイオテクONLINEにて「長崎大学池田教授　日本初の他家TCR療法の医師主導治験を計画中」として長崎大学が進める細胞療法が掲載。
ページのトップへ戻る